All-trans retinoic acid reduces mammalian target of rapamycin via a Sirtuin1-dependent mechanism in neurons

Neuroreport. 2021 Aug 11;32(12):975-982. doi: 10.1097/WNR.0000000000001672.

Abstract

Neuroinflammation has emerged as a key contributor in the pathogenesis of Alzheimer's disease (AD). Mammalian target of rapamycin (mTOR) is a key regulator of metabolism, cell growth and protein synthesis. And an elevated mTOR activity has been detected in AD-affected brain areas. Previous studies have suggested that all-trans retinoic acid (atRA) and rapamycin (RAPA), an mTOR inhibitor, protect lipopolysaccharide (LPS)-induced neuronal inflammation through inhibiting nuclear import of NFκB. The aim of this study was to test the effects of atRA on mTOR expression. Here we discovered that mTOR and p-mTOR expression are elevated in LPS-treated mice or primary rat neurons, while atRA blocks the mTOR gene upregulation via a SIRT1-dependent mechanism. The results of this study demonstrated that atRA may protect LPS-induced neuronal inflammation through suppressing mTOR signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Lipopolysaccharides / toxicity
  • Mice
  • Mice, Inbred C57BL
  • Neurons / drug effects*
  • Neurons / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Sirtuin 1 / biosynthesis*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / biosynthesis*
  • Tretinoin / pharmacology*

Substances

  • Lipopolysaccharides
  • Tretinoin
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases
  • Sirt1 protein, mouse
  • Sirtuin 1